Effect of removal of duplicate isolates on cumulative susceptibility reports

Diagnostic Microbiology and Infectious Disease

Volumn 39, Issue 4, 2001, Pages 251-256

  White, Roger L ^a   Friedrich, Lawrence V ^a   Burgess, David S ^a   Brown, Eve W ^b   Scott, Lynn E ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antibiogram; Duplicates; Surveillance; Susceptibility

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; CEFAZOLIN; CEFOTAXIME; CEFOTETAN; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; PIPERACILLIN; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENTIATION;

ALGORITHMS; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DATA INTERPRETATION, STATISTICAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; HOSPITAL BED CAPACITY, 500 AND OVER; HUMANS; LACTAMS; MICROBIAL SENSITIVITY TESTS; SOFTWARE;

EID: 0034993609     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(01)00225-5     Document Type: Article

References (19)

1. A comparison of antibiotic susceptibility profiles using single and multiple isolates per patient
2. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy
3. Antibiotic resistance in recurrent isolates of gram negative bacilli
4. Antibiotic resistance in bacteria: Mechanisms and consequences
5. Recording of antimicrobial resistance of urinary tract isolates-effect of repeat samples on resistance levels
6. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: Evaluation of a national postmarketing surveillance program
7. Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units
8. Development of resistance during antibiotic therapy
9. The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally
10. Emergence of resistance during therapy with the newer β-lactam antibiotics: Role of inducible β-lactamases and implications for the future
11. Pseudomonas aeruginosa: Changes in antibiotic susceptibility, enzymatic activity, and antigenicity among colonial morphotypes
12. Repeat antimicrobial susceptibility testing of identical isolates